|
Oct 9
|
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
|
|
Sep 18
|
Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis
|
|
Jun 12
|
bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
|
|
Apr 24
|
bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth
|
|
Jan 30
|
bioAffinity Technologies In The News
|
|
Dec 5
|
bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors
|
|
Nov 30
|
CMS Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024
|
|
Nov 28
|
bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post
|
|
Nov 6
|
bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales
|
|
Apr 25
|
bioAffinity Technologies Presents at Cleveland Clinic Lung Cancer Symposium
|